Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS OIG Work Plan: FDA Oversight And DME, Inpatient Payments Make List

This article was originally published in The Gray Sheet

Executive Summary

The Department of Health and Human Services Office of Inspector General 1outlined Oct. 1 more than 300 new and ongoing investigations on its to-do list for fiscal year 2009, including digging into how Medicare pays for durable medical equipment and examinations of hospital inpatient payments and FDA device oversight
Advertisement

Related Content

KCI billing records subpoenaed
KCI billing records subpoenaed
Trial Run Of Expanded Medicare DME Claims Review Planned For FY 2009
HHS Inspector General Advises CMS To Monitor Imaging Growth
Postmarket Surveillance, Durable Equipment Payments On OIG Study List
Postmarket Surveillance, Durable Equipment Payments On OIG Study List
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
Enough Is Enough For New Technology Hospital Payments, MedPAC Says
Advertisement
UsernamePublicRestriction

Register

MT026645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel